Introduction
Most current tumor immunotherapy approaches focus on CD8 C T cells, as these cells can directly and effectively eliminate tumor cells. However, CD4
C T cells are also central to optimal antitumor immunity. 1 Co-transfer of CD4 C and CD8 C T cells enhances CD8
C effector function and therapeutic efficacy in a lymphopenic environment. 2 Similarly, combined vaccination with CD4
C and CD8 C T-cell epitopes augments CD8 C T cell responses and improves clinical outcomes. 3 These effects of CD4 C T cells are mediated through a variety of mechanisms. First, CD4
C T cells provide help for the priming of CD8 C T cell responses in lymphoid organs. Activated CD4 C T cells license antigen-presenting cells, enabling CD8
C T cells to become fully functional cytotoxic T lymphocytes (CTL). 4 Subsequently, tumor-specific CD4 C T cells facilitate accumulation of CD8 C T cells at the effector site and enhance their antitumor activity. 5 
CD4
C T cells are also required for the maintenance of CD8 C T cell numbers, cytotoxic function and cytokine production within the tumor. 6 Finally, CD4 C T-cell help can rescue CTL from activation-induced cell death, promoting effector function and memory formation. 7 In addition to their prominent role in the induction and maintenance of CTL responses, CD4
C T cells can also mediate CD8
C T cell-independent antitumor activity. CD4 C T cells can directly recognize and kill tumor targets, 8 and cytokines produced by CD4 C T cells in tumors, especially IFNg, can promote the antitumor activity of both hematopoietic and non-hematopoietic cells. 9, 10 These cytokine-mediated effects can occur independently of expression of MHCII on tumor cells and therefore do not require direct tumor cell recognition by the CD4 C T cells. 9 Several studies have shown that microbial products, including bacteria and synthetic or natural TLR agonists, promote antitumor immune responses and exhibit antitumor activity in experimental [11] [12] [13] and clinical (reviewed in ref. 14) settings. The activity of these products may be further increased by combination with endogenous danger signals. 15 Treatments that turn the tumor into a site of immune activation are highly attractive as they could be easily applied in the clinic and, if effective, activate antitumor immune responses that are tailored to the patient and of broad specificity. Several of these treatments are known to activate antitumor CD8
C T cells without requiring CD4 C responses 11, 13 whereas for others the capacity to activate CD4 C T cells is unknown. 12 Recruiting the activity of both CD8 C and CD4
C T cells to the tumor should increase the impact of these immunotherapies.
We recently compared the antitumor activity of a range of immune stimulators, and found that effective treatments delayed tumor growth by activating both CD8
C T cells and NK cells. 16 We now report that the same treatments differed in their ability to prime antitumor CD4 C T cell responses, and that this was due to their differential ability to engage IL1bR-dependent signaling. Increased CD4 C T cell priming in the LN was associated with increased tumor infiltration of effector CD4
C T cells and a concomitant decrease in regulatory T cells (Treg), reduced CD8 C T cell exhaustion at the tumor site, and sustained retardation of tumor growth after cessation of therapy. Conversely, blocking IL-1bR or depleting CD4 C T cells abrogated the antitumor activity of MSU C Msmeg. Thus, local immunostimulatory treatments can successfully activate tumor-specific CD4 C T cells and favorably impact on the duration of antitumor CD8 C T cell responses.
Results
Local treatment with poly I:C or MSU C Msmeg delays the growth of B16.OVA tumors
We previously compared a range of immune activating agents for the ability to delay the growth of murine tumors including the B16-F1 melanoma and the 4T1 mammary carcinoma. Treatment of established tumors with poly I:C or a combination of MSU C Msmeg delayed primary tumor growth and reduced lung metastases, whereas several other agents were ineffective. 16 Here, we evaluated the effect of these treatments on the OVAexpressing melanoma B16.OVA. Four local treatments with either poly I:C or MSU C Msmeg significantly reduced the size of B16.OVA tumors at the end of experiment (Fig. 1 ). In contrast, treatments with LPS, LPS and MSU (both not shown), MSU or Msmeg alone ( Fig. 1) did not alter tumor growth compared to PBS controls. Thus, the antitumor activity of poly I:C and MSU C Msmeg on B16.OVA melanomas was similar to that observed in B16-F1 and 4T1 tumors.
Treatment with MSU C Msmeg, but not poly I:C, primes tumor-specific CD4 C T cells in the dLN in an IL-1bR-dependent manner
To determine the effect of poly I:C and MSU C Msmeg treatment on CD4
C T cell responses, we examined the proliferation of CFSE-labeled OTII T cells adoptively transferred into B16. OVA-bearing mice. As previously reported for untreated mice, 17 no OTII proliferation was detected in the dLN of PBS-treated or poly I: C-treated mice ( Fig. 2A) . In contrast, MSU C Msmeg treatment induced significant proliferation of OTII T cells, leading to a higher percentage and number of total and divided OTII cells compared to poly I:C ( Figs. 2A-E) . Proliferation could not be induced by treating with M. smegmatis alone (not shown), and was restricted to the tumor-dLN, suggesting that tumor antigen was necessary for proliferation.
Our previous work showed that treatment with MSU C Msmeg induced detectable amounts of IL-1b in the serum, while poly I:C did not. 16 As IL-1b is known to enhance CD4 C T cell responses, 18 we used the IL-1bR antagonist Anakinra to establish whether IL-1b signaling was critical C T cells in the tumor (Fig. 4A) . These CD4 C T cells showed an increased capacity to produce IFNg and TNF-a, as assessed by intracellular staining without restimulation (Figs. 4B & C), and increased expression of the activation markers CD69 and CD25 in the absence of FoxP3 (Figs. 4D & E) . In contrast, poly I:C treatment did not significantly change any of these parameters compared to PBS controls (Fig. 4) .
As total CD4 C T cells encompass not only effector cells but also Treg, we analyzed the CD4 C T cell infiltrate in B16-F1 melanomas from Foxp3 GFP mice. These mice express a FoxP3-GFP reporter which identifies tumor-infiltrating CD4 C T cells with regulatory function in vitro. 19 In PBStreated tumors, about 20% of the CD4 C T cells were FoxP3-GFP C . After MSU C Msmeg treatment, the frequency of Treg was nearly halved, but remained unchanged after poly I:C administration (Figs. 5A & B) . The reduction in the frequency of Treg in MSU C Msmeg vs. PBStreated tumors was still apparent when calculated as percentage of total live cells in the tumor, suggesting that it was not simply a consequence of the increased proportion of CD4 C effectors (Fig. 5C) . Therefore, treatment with MSU C Msmeg, but not poly I:C, altered the CD4 C infiltrate in tumors, increasing CD4
C effector T cells, and at the same time reducing the proportion of CD4 C Treg.
Enhanced CD4
C T cell responses after MSU C Msmeg treatment reduce exhaustion of tumor-infiltrating CD8 C T cells To assess whether the enhanced CD4
C T cell response in MSU C Msmeg-treated mice influenced the quality of tumorinfiltrating T cells, we examined the expression of the exhaustion marker PD-1 on intratumoral CD4
C and CD8 C T cells. In PBS-treated controls, the proportion of intratumoral CD4 C -sufficient mice, mice treated with anti-CD4 one day before the start of immunotherapy had much higher frequencies of PD-1 C CD8 C T cells in their tumors (Fig. 6C) , indicating that CD4 C T cells have a large impact on PD-1 expression by CD8 C T cells. However, even after CD4
C T cell depletion, treatment with MSU C Msmeg reduced PD-1 expression on CD4 C T cells compared to PBS controls, suggesting that MSU C Msmeg can also exert additional, CD4
C T cell-independent effects that help prevent CD8 C T cell exhaustion (Fig. 6C ).
MSU C Msmeg treatment induces sustained antitumor immunity in a CD4
C T cell and IL-1bR dependent manner Activation of CD4 C T cell responses and the consequent reduction of CD8 C T cell exhaustion may result in prolonged antitumor activity. To investigate this possibility, we switched from the B16 melanoma model to the more immunogenic E.G7-OVA and EL-4 thymomas, as these tumor models might enable a more sensitive detection of immune responses at the later stages of tumor growth. Repeated peritumoral administrations of both poly I:C and MSU C Msmeg similarly delayed tumor growth during the course of treatment (day 4-14, Fig. 7A ).
However, after cessation of treatment, poly I:C-treated tumors resumed growth at a rate comparable to that of PBS-treated controls. In contrast, MSU C Msmeg-treated tumors continued to grow at a reduced rate (Fig. 7A) , and MSU C Msmegtreated mice survived significantly longer than poly I:C-treated mice (Fig. 7B) . Depletion of CD4 C T cells just before the commencement of treatment completely abrogated the MSU C Msmeg induced antitumor activity (Figs. 7C, D) . In contrast, tumor growth and survival of PBS control and poly I:C treated groups was unchanged by CD4 C depletion (Figs. 7C, D) . Depletion of CD4 C T cells after the fourth of 6 peri-tumoral MSU C Msmeg treatments led to faster tumor growth and worse survival compared to the nondepleted MSU C Msmeg treated group (Figs. 7C, D, day 10 depleted groups). These results suggest that CD4
C T cells play a critical ongoing role in MSU C Msmeg induced antitumor immunity that extends beyond the priming phase of CD8 C T cells.
We also assessed the effect of blocking IL-1bR on tumor growth and the effect of immunotherapy. In line with our observation that IL-1bR activity was necessary for the priming of tumor-specific CD4 C T cells (Fig. 3) , blocking IL-1bR during MSU C Msmeg treatment of EL-4 thymomas abolished the antitumor effect (Figs. 7E, F) . In contrast, tumor growth and survival in poly I:C treated groups were not affected by IL-1bR blockade (Figs. 7E, F) . 
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These data show that the sustained antitumor activity conferred by treatment with MSU C Msmeg requires IL-1bR signaling and the ongoing presence of CD4 C T cells, thus conferring a significant host survival benefit compared to treatments, such as polyI:C, that fail to support CD4 C T cell priming.
Discussion
In this study we compare different immune activating agents for ability to support the priming of CD4
C T cell responses to tumor-derived antigens. Previous work demonstrated that the OVAexpressing tumors B16.OVA and E.G7-OVA 17, 20 are unable to induce the proliferation of OVA-specific OTII CD4
C T cells in vivo, suggesting a defective function of tumor-associated DC. Here we report that treatment with MSU C Msmeg, but not poly I:C, can restore CD4
C T cell priming and increase tumor homing and intratumoral cytokine production by CD4 C T cells. We also show that increased CD4 C T cell priming by MSU C Msmeg was associated with decreased proportions of intratumoral Treg, and reduced expression of PD-1 on CD4
C and CD8 C T cells in tumors. Therefore, treatment with selected immune activating agents can enhance presentation of tumor antigen, and restore immune reactivity in the tumor context.
We previously reported that MSU C Msmeg and poly I:C can both delay tumor growth by a mechanism which requires intact CD8 C and NK cell responses. 16 However, as shown in this paper, only MSU C Msmeg supports CD4 C T cell priming and requires CD4
C T cells for its antitumor effect. In contrast, CD4
C T cell responses were not involved in the antitumor effect of poly I:C, as also described in the literature using a malignant mesothelioma tumor model. 11 The differential capacity to induce CD4 C T cell priming can be explained by the selective ability of MSU C Msmeg to elevate the levels of IL-1b in serum, 16 as blocking IL-1b signaling in vivo using the IL-1bR antagonist Anakinra significantly reduced CD4 C T cell proliferation and selectively abrogated the MSU C Msmeg but not the poly I:C induced antitumor effect. IL-1b is known to enhance CD4 C T cell responses 18 and promotes induction of antitumor immunity, 21, 22 however, its effects on CD4 C T cell responses have not been examined in a tumor context. IL-1b can enhance CD4 C T cell priming both via effects on antigen-presenting cells 23 and through direct signaling in CD4 C T cells, leading to increased proliferation and cytokine production. 24 Furthermore, IL-1b can activate MyD88 signaling in CD4 C T cells, rendering them refractory to Treg-mediated suppression and increasing their effector function. 25 Any of these IL-1b effects could be contributing to the improved CD4 C T cell response we report here.
In addition to increasing the proportion of effector CD4 C T cells in tumors, MSU C Msmeg treatment also reduced the frequency of Treg. This lower frequency may have been purely due to reduced Treg accumulation in the tumor. It is also possible that MSU C Msmeg treatment maintained T effector function and reduced conversion of effector T cells to Treg. Alternatively, MSU C Msmeg treatment may reprogram induced Treg to an effector-like phenotype with downregulation of FoxP3-GFP expression. Downregulation of FoxP3 by IL-1b and IL-6 has been reported in an elegant study using reporter mice, and could also be induced by vaccination with antigen in CFA. 26 Therefore, the induction of IL-1b by MSU C Msmeg, possibly in combination with other pro-inflammatory signals also elicited by this treatment, may be a contributing factor in the reprogramming of Treg to CD4 C effector cells. Recent evidence suggests that in some situations reprogrammed Treg may be essential for providing help for antitumor CD8
C T cell responses and effective vaccination. 27 The concomitant increase in tumor-infiltrating effector T cells and decrease in Treg in MSU C Msmeg-treated mice resulted in an increased T effector/Treg ratio in tumors. It has been shown that the ratio of T effectors to Treg, rather than just activation of effector cells, is critical for improved antitumor immunity in mice. 28 In addition, clinical studies in different types of cancer report improved survival with increased T effector to Treg ratios [29] [30] [31] even when the absolute counts of Treg or T effector cells were not indicative of outcome. 32 Thus the relative presence of effector cells over suppressive cells in tumors is critical for successful antitumor immunity, and treatments such as MSU C Msmeg, which affect both effector and Treg, offer a particularly promising approach to tumor immunotherapy.
We have previously shown that MSU C Msmeg and poly I:C could both stimulate tumor-specific CD8 C T cell proliferation and CD8
C T cell infiltration into tumors. 16 However, poly I:C was unable to stimulate CD4 C T cell priming and its antitumor activity was unaltered by CD4 C T cell depletion. As also proposed by others, 11, 13 these observations suggest that poly I:C is capable of inducing some level of CD4-independent CD8 C T cell priming. The extent of CD8 C T cell priming and tumor infiltration, however, was more pronounced in response to MSU C Msmeg, 16 and in this case depletion of CD4 C T cells before or C T cells were dispensable for CD8 C T cell priming, but were required for maintenance of the CD8 C response including tumor infiltration and cytokine production. 6 The sustained antitumor activity of CD8 C T cells in the presence of CD4 C T cells might result, at least in part, from decreased expression of exhaustion markers such as PD-1 on CD8 C T cells. 7 In our experiments on untreated mice, the proportion of PD-1-expressing tumor-infiltrating CD8 C T cells increased substantially with tumor progression. This increase was not changed after poly I:C treatment, but was significantly reduced in response to MSU C Msmeg. Depletion of CD4 C T cells greatly increased the percentage of PD-1-expressing intratumoral CD8 C T cells, indicating that CD4 C T cells indeed play a critical role in preventing PD-1 upregulation on CD8
C effectors. However, in CD4 Cdepleted mice, MSU C Msmeg-treated tumors still showed a reduced frequency of PD-1 high CD8
C T cells compared to PBS controls. This suggests that MSU C Msmeg can maintain CD8 C T cell function through additional mechanisms that do not require CD4 C T cells, possibly including the effects of cytokines and/ or IL-1b on DC 33, 34 or directly on CD8 C T cells. 35 Consistent with an improved maintenance of antitumor CD8
C T cell activity, we observed sustained antitumor activity against murine thymomas only after MSU C Msmeg, but not poly I:C, treatment, and this was 
CD4
C T cell dependent. Similarly, other authors reported increased antitumor CD8
C responses in mice treated with poly I: C and anti-PD-L1 antibodies. 36 In parallel to its effect on CD8 C T cells, MSU C Msmeg treatment also kept the proportion of PD-1-expressing CD4 C T cells low throughout tumor progression. Although the association of PD-1 expression with exhaustion is not as firmly established in CD4
C T cells as in CD8 C T cells, several studies have now linked functional impairment of CD4 C T cells with high levels of PD-1 expression. [37] [38] [39] For example, in a model of recurrent melanoma, blocking the PD-1 ligand PD-L1 in combination with Treg depletion restored CD4
C effector function and resulted in tumor eradication in the absence of CD8 C T cells. 39 These findings illustrate the functional importance of PD-1 expression on tumor-infiltrating CD4 C T cells. Recent successes in clinical trials blocking PD-1 or its ligands further underscore the significance of this pathway for the activation of effective antitumor immunity. 40, 41 In conclusion, we show that treatment with MSU C Msmeg leads to the activation of a substantial CD4
C T cell response, reduced Treg infiltration in tumors, improved CD8
C T cell activity, and reduced T cell exhaustion resulting in sustained antitumor immunity. MSU has been found to be safe as a vaccine adjuvant for use in humans. 42 Mycobacteria such as Bacillus Calmette-Gu erin are already used in the clinic for the treatment of bladder cancer, 43 and their safety in immune-compromised cancer patients can be further improved by replacing with non-pathogen derived species such as Msmeg 44 or by heatkilling. 16 We conclude that, on the basis of its efficacy and safety profile, MSU C Msmeg would be a useful basis for immune stimulatory treatments, also in combination with other immunotherapies or chemotherapy, to promote and sustain anticancer immunity. CFU Mycobacterium smegmatis (Msmeg mc 2 155) combined with 250 mg MSU (endotoxin < 0.01 EU/10 mg) were given in a total volume of 100 ml PBS injected in the area directly adjacent to the tumors as described.
Materials and Methods

Mice
16 PBS (Invitrogen) was used as a vehicle control. Treatment was started once the tumor became palpable (day 4-9, depending on tumor and experiment) and given every second day for 4 to 6 times. This schedule was chosen on the basis of preliminary experiments comparing tumor size and survival after treatment.
Flow cytometry
Lymph nodes (LN) or tumors were digested using DNase I and Liberase TL (Roche). Single cell preparations were resuspended in Flow buffer (PBS with 10mM EDTA, 2% FBS and 0.01% NaN 3 ) and pretreated with anti-mouse CD16/32 (2.4G2) before staining with antibodies specific for the following markers: CD45 (30F11), CD45.1 (A20), CD4 (RM4-5), CD3e (2C11), CD8a (53-6.7), CD25 (PC61), CD69 (H1.2F3), Va2 (B20.1) (all BD Biosciences), PD-1 (RMP1-30) from Biolegend and CD4 (GK1.5) prepared in-house. Streptavidin-PE or PETexas-Red (BD Biosciences) were used to reveal biotinylated antibodies. Dead cells were identified by DAPI or Live/Dead Fixable blue (Invitrogen) exclusion. For intracellular cytokine staining, cell suspensions were incubated for 6 h in Golgi Stop without restimulation. Cells were then stained for surface markers, followed by intracellular staining with anti-IFNg (XMG1.2) and anti-TNF-a (MP6-XT22) antibodies, or isotype controls (R3-34 or EBRG1), using the BD Cytofix/Cytoperm kit (all from BD Biosciences). Acquisition was performed on a BD LSRII SORP (Becton Dickinson) and data were analyzed using FlowJo version 9.7.4 (Tree Star).
In vivo T cell proliferation assay Anti-CD4 microbeads (Miltenyi Biotech) were used to positively select CD4 C T cells from spleens and LNs of OTII x B6. SJL-Ptprc a mice. CD4 C T cells were subsequently labeled with CFSE as described 50 and 1 -2 £ 10 6 cells were injected i.v. into C57BL/6J hosts bearing established B16.OVA tumors. OTII proliferation was assessed in tumor-dLNs 5 d later.
CD4
C T cell depletion CD4 C T cells were depleted by i.p. injection of 2 £ 250mg of purified anti-CD4 (GK1.5) antibody as indicated in the figures. Depletion of CD4 C T cells was assessed in blood during the experiment and in some tumors on day 15, and was consistently >92%.
IL-1bR blocking
For IL-1bR blockade, mice were given daily i.p. injections of 100 mg/kg of the IL-1bR antagonist Anakinra (Swedish Orphan Biovitrum AB, Stockholm, Sweden) in sterile PBS on the days indicated in the figures.
Statistics
Statistical analyses were performed using Prism 5.0 software (GraphPad). Means § SE are shown in all graphs. Unless otherwise indicated, data were compared using the Kruskal-Wallis test with Dunn's multiple comparison test. Tumor growth data was analyzed by 2-way-ANOVA with Bonferroni's post test. Survival data was analyzed using the log-rank test with Bonferroni's correction for multiple testing. Differences of p < 0.05 were deemed significant (*), p < 0.01 very significant (**) and p < 0.001 extremely significant (***).
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